GSK shares hit 3-month high as Q2 earnings beat forecasts, driven by strong vaccine sales and pipeline investment.
GSK's shares rose to a three-month high after the company reported better-than-expected second-quarter results, with revenue up 5% to £8.41 billion and adjusted earnings per share increasing 9% to 50.5p. Vaccine sales grew 8%, notably with Shingrix a...
